Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.82 |
| ▸ | FPR2 | P25090 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | RAD52 | P43351 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL1897003 | 1.00 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL24866 | 1.00 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29430171 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL41194 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29579627 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL23039392 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL341516 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL466955 | 0.98 | FPR2 (0.96) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL21445272 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL28329317 | 0.95 | FPR2 (0.90) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-20230174613-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2023-06-08 | — | — | US | claimed |
| US-11542315-B2 | Methods and compositions for treating diseases and disorders of the nervous system | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-03 | — | — | US | claimed |
| US-12630602-B2 | Methods and compositions for treating diseases and disorders of the nervous system | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CHILDREN'S MEDICAL CENTER CORPORATION | 2025-04-22 | — | — | US | disclosed |
| CN-119677724-A | Crystalline forms of 1,2, 4-oxadiazole fungicides | 先正达农作物保护股份公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118368985-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117099786-A | Substituted 3, 4-dihydropyrimidin-2 (1H) -ones as seed treatment agents | 阿达玛马克西姆股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230174613-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2023-06-08 | — | — | US | disclosed |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| CN-113782718-B | High-voltage lithium ion battery material, lithium ion battery and preparation method thereof | 上海空间电源研究所 | 2023-02-03 | — | — | CN | disclosed |
| US-11542315-B2 | Methods and compositions for treating diseases and disorders of the nervous system | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11446353-B2 | Compositions and methods for the treatment of fungal infections | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220152041-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | DRD2 1173/4885HTR2A 1024/4885HTR2C 1330/4885 |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CALM1, RACK1, RRBP1 | DRD2 3409/4885HTR2A 3286/4885HTR2C 4134/4885 |
| US-12630602-B2 | Methods and compositions for treating diseases and disorders of the nervous system | CHRNA4, MCHR2, HTR3D | DRD2 142/4885HTR2A 94/4885HTR2C 73/4885 |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | DRD2 3379/4885HTR2A 3131/4885HTR2C 4023/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | DRD2 1173/4885HTR2A 1024/4885HTR2C 1330/4885 |
| US-20220152041-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CALM1, RACK1, RRBP1 | DRD2 3409/4885HTR2A 3286/4885HTR2C 4134/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | DRD2 1173/4885HTR2A 1024/4885HTR2C 1330/4885 |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | DRD2 1173/4885HTR2A 1024/4885HTR2C 1330/4885 |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CALM1, RACK1, CAMK2B | DRD2 3379/4885HTR2A 3131/4885HTR2C 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.